Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma

Open access
Kalish, Jennifer M., Doros, Leslie, Helman, Lee J., Hennekam, Raoul C., Kuiper, Roland P., Maas, Saskia M., Maher, Eamonn R., Nichols, Kim E., Plon, Sharon E., Porter, Christopher C., Rednam, Surya, Schultz, Kris Ann P., States, Lisa J., Tomlinson, Gail E., Zelley, Kristin, Druley, Todd E. · 2017 · Clinical Cancer Research

Abstract

A number of genetic syndromes have been linked to increased risk for Wilms tumor (WT), hepatoblastoma (HB), and other embryonal tumors. Here, we outline these rare syndromes with at least a 1% risk to develop these tumors and recommend uniform tumor screening recommendations for North America. Specifically, for syndromes with increased risk for WT, we recommend renal ultrasounds every 3 months from birth (or the time of diagnosis) through the seventh birthday. For HB, we recommend screening with full abdominal ultrasound and alpha-fetoprotein serum measurements every 3 months from birth (or the time of diagnosis) through the fourth birthday. We recommend that when possible, these patients be evaluated and monitored by cancer predisposition specialists. At this time, these recommendations are not based on the differential risk between different genetic or epigenetic causes for each syndrome, which some European centers have implemented. This differentiated approach largely represents distinct practice environments between the United States and Europe, and these guidelines are designed to be a broad framework within which physicians and families can work together to implement specific screening. Further study is expected to lead to modifications of these recommendations. Clin Cancer Res; 23(13); e115–e22. ©2017 AACR. See all articles in the online-only CCR Pediatric Oncology Series.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0710

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 205

Metadata

Authors
Kalish, J. M., Doros, L., Helman, L. J., Hennekam, R. C., Kuiper, R. P., Maas, S. M., Maher, E. R., Nichols, K. E., Plon, S. E., Porter, C. C., Rednam, S., Schultz, K. A. P., States, L. J., Tomlinson, G. E., Zelley, K., & Druley, T. E.
Venue
Clinical Cancer Research
Published
2017-07-01
Volume
23
Issue
13
Pages
e115-e122
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2732125702
Cited by
205
References
1
FWCI
5.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0710
The paper
Kalish, J. M., Doros, L., Helman, L. J., Hennekam, R. C., Kuiper, R. P., Maas, S. M., Maher, E. R., Nichols, K. E., Plon, S. E., Porter, C. C., Rednam, S., Schultz, K. A. P., States, L. J., Tomlinson, G. E., Zelley, K., & Druley, T. E. (2017). Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.